Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | G6PD | P11413 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL917457 | 1.00 | MEN1 (0.61) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL914606 | 0.91 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL924522 | 0.91 | MEN1 (0.60) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| Acetic Acid SCHEMBL914864 | 0.91 | RAB9A (0.56) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| Acetic Acid SCHEMBL914865 | 0.91 | RAB9A (0.56) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9618643 | 0.90 | MEN1 (0.58) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9618642 | 0.90 | MEN1 (0.58) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| Acetic Acid SCHEMBL11512881 | 0.86 | SMN1; SMN2 (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| Acetic Acid SCHEMBL11512883 | 0.86 | SMN1; SMN2 (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| Acetic Acid SCHEMBL21519499 | 0.84 | NPC1 (0.55) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | claimed |
| EP-1313461-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | Melacure Therapeutics AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002011715-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MELACURE THERAPEUTICS AB (SE) | 2002-02-14 | — | — | WO | claimed |
| US-5272165-A | 2-alkylidene-aminoguanidines and methods of use therefor | THE ROCKEFELLER UNIVERSITY (US) | 1993-12-21 | — | — | US | claimed |
| WO-1992019236-A1 | 2-ALKYLIDENE-AMINOGUANIDINES FOR INHIBITING ADVANCED NONENZYMATICGLYCOSYLATION OF PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1992-11-12 | — | — | WO | claimed |
| US-5130324-A | For inhibiting nonezymatic crosslinking of glycosylation products of proteins | THE ROCKEFELLER UNIVERSITY (US) | 1992-07-14 | — | — | US | claimed |
| US-12006294-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-06-11 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-9227927-B2 | Method of treating inflammation | ANAMAR AB (SE) | 2016-01-05 | — | — | US | disclosed |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | HPF IP HOLDING S.A. (LU) | 2013-11-07 | — | — | US | disclosed |
| US-8410174-B2 | Method for treating arthritis | ANAMAR AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-8309609-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-11-13 | — | — | US | disclosed |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | ANAMAR AB (SE) | 2012-07-12 | — | — | US | disclosed |
| WO-2002011715-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MELACURE THERAPEUTICS AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
| US-5272165-A | 2-alkylidene-aminoguanidines and methods of use therefor | THE ROCKEFELLER UNIVERSITY (US) | 1993-12-21 | — | — | US | disclosed |
| US-5243071-A | Acetoacetic acid guanyl hydrazone; inhibits food spoilage and protein aging | THE ROCKEFELLER UNIVERSITY (US) | 1993-09-07 | — | — | US | disclosed |
| WO-1992019236-A1 | 2-ALKYLIDENE-AMINOGUANIDINES FOR INHIBITING ADVANCED NONENZYMATICGLYCOSYLATION OF PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1992-11-12 | — | — | WO | disclosed |
| US-5130324-A | For inhibiting nonezymatic crosslinking of glycosylation products of proteins | THE ROCKEFELLER UNIVERSITY (US) | 1992-07-14 | — | — | US | disclosed |
| US-4139555-A | Recovery of (1-S)-2-oxo-bornane-10-sulphonate | BAYER AKTIENGESELLSCHAFT (DE) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | MEN1 4058/4885KMT2A 3083/4885RAB9A 497/4885 |
| US-12006294-B2 | Therapeutic compounds | OPRL1, INA, OGFR | MEN1 4058/4885KMT2A 3083/4885RAB9A 497/4885 |
| US-20130295009-A1 | METHOD OF TREATING INFLAMMATION | MC2R, MC5R, MC1R | MEN1 2718/4885KMT2A 3098/4885RAB9A 3123/4885 |
| US-20120178820-A1 | METHOD FOR TREATING ARTHRITIS | MC5R, MC1R, MC2R | MEN1 1696/4885KMT2A 2794/4885RAB9A 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.